Buy Rubraca (rucaparib) Online For Sale
From $1,538.00Buy Zejula (niraparib) Online For Sale
From $4,561.00Buy Ninlaro (ixazomib) Online For Sale
DISEASE INDICATIONS: Multiple Myeloma
MANUFACTURER: Takeda Pharma A/S
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA)
Therapeutic Goods Administration (TGA)
Ninlaro (ixazomib) is a medication used in combination with lenalidomide and dexamethasone to treat people with multiple myeloma who have undergone one to three previous lines of therapy.
Buy Odomzo (sonidegib) Online For Sale
DISEASE INDICATIONS: Skin Cancer
MANUFACTURER: Sun Pharmaceutical Industries Europe B.V.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Odomzo (sonidegib) is a medication used to treat locally advanced basal cell carcinoma (BCC). It is taken once daily at two possible dosages – 200mg or 800mg.
Buy Onivyde (irinotecan hydrochloride trihydrate) Online For Sale
DISEASE INDICATIONS: Pancreatic Cancer
MANUFACTURER: Baxalta Innovations GmbH
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Onivyde (irinotecan hydrochloride trihydrate) is a chemotherapy drug used to treat metastatic adenocarcinoma of the pancreas that has worsened despite previous cancer treatment containing gemcitabine.
Buy Portrazza (necitumumab) Online For Sale
DISEASE INDICATIONS: Lung Cancer
MANUFACTURER: Eli Lilly Nederland B.V.
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Portrazza (necitumumab) is a medication approved for the treatment of advanced squamous non-small cell lung cancer. It is used in combination with the chemotherapies gemcitabine and cisplatin.
Buy Rubraca (rucaparib) Online For Sale
DISEASE INDICATIONS: Gynaecological Cancer
MANUFACTURER: Clovis Oncology, Inc.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Rubraca (rucaparib) is a medication used to treat certain types of ovarian cancer, including advanced ovarian cancer that has relapsed or progressed despite previous treatment.
Buy Rydapt (midostaurin) Online For Sale
DISEASE INDICATIONS: Leukemia
MANUFACTURER: Novartis Europharm Limited
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Rydapt (midostaurin) is prescribed to treat newly diagnosed acute myeloid leukemia (AML), aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL) in patients.
Buy Zejula (niraparib) Online For Sale
DISEASE INDICATIONS: Gynaecological Cancer
MANUFACTURER: Tesaro UK Limited
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Zejula (niraparib) is a drug used for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients who have responded to platinum-based chemotherapy.
Buy Lynparza (Olaparib) Online For Sale
DISEASE INDICATIONS: Breast Cancer, Gynaecological Cancer
MANUFACTURER: AstraZeneca AB
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Medsafe (NZ)
Lynparza is an oral medication used to treat some types of cancer by blocking the action of the PARP enzyme, preventing cancer cells from multiplying. It is used for ovarian, breast, and pancreatic cancer patients with a BRCA gene mutation or triple-negative breast cancer.
Buy Tecentriq (Atezolizumab) Online For Sale
Tecentriq (Atezolizumab) is an immune checkpoint inhibitor used in conjunction with chemotherapy or other cancer medications to attack cancer cells. By blocking PD-L1, a protein on some cancer cells, Tecentriq allows the immune system to recognize and target cancer cells. Clinical trials show that Tecentriq extends survival and improves outcomes in patients with lung cancer, bladder cancer, and triple-negative breast cancer. Tecentriq is generally well-tolerated, administered intravenously once every three or four weeks, and monitored for potential side effects. Tecentriq is FDA-approved for several types of cancer, making it a promising treatment option for many cancer patients.